My tactical idea is a top 6 mover 🏆

I flagged it Friday — today, it exploded.

TODAY’S TOP ALERT! 

Citius Pharma (Nasdaq: CTXR)

👉  CTXR is TODAY’S #1 ALERT 👈

Hey there, Folks,

I hope your week is off to a GREAT start.

The market certainly wasn’t this morning, though it has trended up since about 10:00 am EST and is now threatening to turn positive for the day.

Even with the markets down, I’ve been thrilled with how my “tactical trade” idea has played out today.

Citius Pharmaceuticals (CTXR) caught my eye on Friday, when it ripped 19% even as the market tanked.

But what happened this morning caught me by surprise…

When I was putting my finishing touches on my writeup, I noticed that its ~92%-owned subsidiary, Citius Oncology, Inc. (CTOR), was up 67% in the pre-market, and had been up as high as 172%.

As I wrote to you, “The underlying value of CTXR is actually up tremendously this morning because of the massive amount of CTOR stock they own — and the stock price isn’t reflecting that (yet).”

This was a massive opportunity, and I hope you locked into it quickly, because this is what we’re looking at as of lunchtime:

CTXR was one of the top movers in the entire market, and if you look at #3, that’s its majority-owned subsidiary!

This is an awesome day for Citius — both Pharmaceuticals and Oncology — and I’m glad I was able to put it on your radar before the opening bell.

These “tactical” ideas don’t always work out, but I’ve landed some truly stellar ones lately, even amid some of the worst market-wide performance in years.

In my view, it’s always fun to do your own research on these ideas and see if they appeal to you, then watch how they play out.

I’m eager to see where CTXR (and CTOR!) goes from here.

Stay tuned!

To Your Success,

Jeff Bishop

*Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on March 31, 2025.  Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on February 19, 2025.  Before that, we received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on September 23, 2024, and we also received twenty five thousand dollars (cash) from Sica Media for advertising Citius Pharmaceuticals for a one day marketing program starting on July 11, 2024 as well as fifteen thousand dollars via ach bank transfer by Lifewater Media for advertising Citius Pharmaceuticals for a one marketing program on March 9th, 2023. These amounts were paid by someone else not connected to Citius Pharmaceuticals. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither RagingBull nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into Citius Pharmaceuticals might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, 

Neither Raging Bull nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.